Fokale Therapie des Prostatakarzinoms
详细信息 查看全文
- 作者：V. Kasivisvanathan MBBS ; BSc ; MRCS (1) (2)
T.T. Shah (1) (2)
I. Donaldson (1) (2)
A. Kanthabalan (1) (2)
C.M. Moore (1) (2)
M. Emberton (1) (2) (3)
H.U. Ahmed (1) (2)
1. Division of Surgery and Interventional Sciences ; University College London ; 4th Floor ; Room 4.23 ; 132 Hampstead Road ; NW1 2PS ; London ; UK
2. Urology Department ; University College London Hospitals Trust ; London ; UK
3. NIHR UCLH/UCL Comprehensive Biomedical Research Centre ; London ; UK - 关键词：Fokale Therapie ; Prostatakarzinom ; Gewebeerhaltender Ansatz ; Funktionelles Ergebnis ; Onkologisches Ergebnis ; Focal therapy ; Prostate neoplasm ; Tissue ; preserving approach ; Functional outcome ; Oncological outcome
- 刊名：Der Urologe A
- 出版年：2015
- 出版时间：February 2015
- 年：2015
- 卷：54
- 期：2
- 页码：202-209
- 全文大小：489 KB
- 参考文献：1. Ahmed HU, Arya M, Freeman A et al (2012) Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol 13:e509鈥揺517 2045(12)70388-1" target="_blank" title="It opens in new window">CrossRef
2. Ahmed HU, Berge V, Bottomley D et al (2014) Can we deliver randomized trials of focal therapy in prostate cancer? Nat Rev Clin Oncol 11:482鈥?91 2014.44" target="_blank" title="It opens in new window">CrossRef
3. Ahmed HU, Emberton M (2012) Focal HIFU for prostate cancer鈥攁uthors鈥?reply. Lancet Oncol 13:e284 2045(12)70307-8" target="_blank" title="It opens in new window">CrossRef
4. Barqawi AB, Stoimenova D, Krughoff K et al (2014) Targeted focal therapy for the management of organ confined prostate cancer. J Urol 192:749鈥?53 2014.03.033" target="_blank" title="It opens in new window">CrossRef
5. Catto JW, Robinson MC, Albertsen PC et al (2011) Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer 105:931鈥?37 2011.314" target="_blank" title="It opens in new window">CrossRef
6. Cooperberg MR, Lubeck DP, Meng MV et al (2004) The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22:2141鈥?149 200/JCO.2004.10.062" target="_blank" title="It opens in new window">CrossRef
7. Dall鈥檈ra MA, Albertsen PC, Bangma C et al (2012) Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 62:976鈥?83 2012.05.072" target="_blank" title="It opens in new window">CrossRef
8. De Visschere PJ, De Meerleer GO, Futterer JJ et al (2010) Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol 194:1427鈥?433 2214/AJR.10.4263" target="_blank" title="It opens in new window">CrossRef
9. Donaldson IA, Alonzi R, Barratt D et al (2014) Focal therapy: patients, interventions, and outcomes-a report from a consensus meeting. Eur Urol 2014 Sep 30. pii: S0302鈥?838(14)00955-5. doi: 10.1016/j.eururo.2014.09.018 (Epub ahead of print)
10. Durand M, Barret E, Galiano M et al (2014) Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int 113:56鈥?4 2370" target="_blank" title="It opens in new window">CrossRef
11. Hale Z, Miyake M, Palacios DA et al (2013) Focal cryosurgical ablation of the prostate: a single institute鈥檚 perspective. BMC Urol 13:2 2490-13-2" target="_blank" title="It opens in new window">CrossRef
12. Hirst AM, Frame FM, Maitland NJ et al (2014) Low temperature plasma: a novel focal therapy for localized prostate cancer? Biomed Res Int 2014:878319 2014/878319" target="_blank" title="It opens in new window">CrossRef
13. Kasivisvanathan V, Dufour R, Moore CM et al (2013) Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol 189:860鈥?66 2012.10.009" target="_blank" title="It opens in new window">CrossRef
14. Kasivisvanathan V, Emberton M, Ahmed HU (2013) Focal therapy for prostate cancer: rationale and treatment opportunities. Clin Oncol (R Coll Radiol) 25:461鈥?73
15. Kletscher BA, Qian J, Bostwick DG et al (1995) Prospective analysis of multifocality in renal cell carcinoma: influence of histological pattern, grade, number, size, volume and deoxyribonucleic acid ploidy. J Urol 153:904鈥?06 22-5347(01)67600-6" target="_blank" title="It opens in new window">CrossRef
16. Lee T, Mendhiratta N, Sperling D et al (2014) Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. Rev Urol 16:55鈥?6
17. Li YH, Elshafei A, Agarwal G et al (2014) Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry. Prostate: 2014 Oct 4. doi: 10.1002/pros.22881 (epub ahead of print)
18. Moore CM, Kasivisvanathan V, Eggener S et al (2013) Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol 64:544鈥?52 2013.03.030" target="_blank" title="It opens in new window">CrossRef
19. Onik G, Barzell W (2008) Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol 26:506鈥?10 2008.03.005" target="_blank" title="It opens in new window">CrossRef
20. Oto A, Sethi I, Karczmar G et al (2013) MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology 267:932鈥?40 21652" target="_blank" title="It opens in new window">CrossRef
21. Piersanti M, Ezzat S, Asa SL (2003) Controversies in papillary microcarcinoma of the thyroid. Endocr Pathol 14:183鈥?91 2022-003-0011-5" target="_blank" title="It opens in new window">CrossRef
22. Resnick MJ, Koyama T, Fan KH et al (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368:436鈥?45 209978" target="_blank" title="It opens in new window">CrossRef
23. Singh PB, Anele C, Dalton E et al (2014) Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy. Eur Urol 66:12鈥?9 2013.09.045" target="_blank" title="It opens in new window">CrossRef
24. Valerio M, Ahmed HU, Emberton M et al (2014) The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol 66:732鈥?51 2013.05.048" target="_blank" title="It opens in new window">CrossRef
25. Valerio M, Dickinson L, Ali A et al (2014) A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Contemp Clin Trials 39:57鈥?5 2014.07.006" target="_blank" title="It opens in new window">CrossRef
26. Valerio M, Stricker PD, Ahmed HU et al (2014) Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis 17(4):343鈥?47 2014.33" target="_blank" title="It opens in new window">CrossRef
27. Van Velthoven R, Aoun F, Limani K et al (2014) Primary zonal high intensity focused ultrasound for prostate cancer: results of a prospective phase IIa feasibility study. Prostate Cancer 2014:756189
28. Villers A, Puech P, Mouton D et al (2006) Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 176:2432鈥?437 2006.08.007" target="_blank" title="It opens in new window">CrossRef
29. Wilt TJ, Brawer MK, Jones KM et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203鈥?13 2" target="_blank" title="It opens in new window">CrossRef
30. Wilt TJ, Macdonald R, Rutks I et al (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 148:435鈥?48 26/0003-4819-148-6-200803180-00209" target="_blank" title="It opens in new window">CrossRef - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Urology and Andrology - 出版者：Springer Berlin / Heidelberg
- ISSN：1433-0563
文摘
Focal therapy is a treatment strategy for men with localized prostate cancer that may serve as an alternative option to radical therapy. A number of minimally invasive ablative technologies are available to deliver treatment, and the energies most commonly used include high-intensity focused ultrasound and cryotherapy. The benefit of a tissue-preserving approach is the limitation of damage to key structures such as the neurovascular bundles, external urinary sphincter, rectal mucosa and bladder neck. This in turn minimizes side effects typically associated with radical therapies whilst also aiming to maintain oncological control. Over 30 single-centre studies of focal therapy have been published to date reporting excellent continence rates, good potency rates and acceptable short-term oncological outcomes. However, there are a number of controversial aspects associated with focal therapy including the index lesion hypothesis, patient selection criteria, assessment of treatment effect and the lack of medium- and long-term oncological outcomes. In the process of the adoption of new technology, there is a limited window of opportunity to provide this evidence in well-designed prospective trials. Men should be allowed to benefit from the potential advantages of this novel treatment whilst under close surveillance. An English version of this article is available under dx.doi.org/10.1007/s00120-014-3734-7.